Sulphonylureas and Weight Gain
Sulphonylureas, the long-established tablets for type 2 diabetes, typically add one to two and a half kilograms in the first year of treatment, which matters when weight is part of the treatment goal.
Plain English
Patient-Friendly Explanation
Sulphonylureas, which include gliclazide, glipizide and glibenclamide, are among the oldest and most widely used tablets for type 2 diabetes, and they are still dispensed in large numbers in Singapore because they work, they have decades of safety data behind them, and they are inexpensive. They act by prompting the pancreas to release more insulin. That is also why they tend to add weight. More circulating insulin encourages the body to store the energy it takes in, some of it as fat; the tablets can also lower blood sugar enough to cause hunger and extra eating, and they cause some fluid retention. The result is a modest but fairly predictable rise. In the ADOPT trial, which compared three medicines as first-line treatment in more than 4,000 people with newly diagnosed type 2 diabetes followed for about four years, those taking glibenclamide gained on average 1.6 kg in the first year and then levelled off. In the long UKPDS study, weight gain was greatest with insulin, less with a sulphonylurea, and least with metformin. Typical figures across trials are one to four kilograms over six to twelve months. The gain is not in itself a reason to refuse these tablets, because for many people the blood-sugar benefit is worth more than the kilograms, but it is a reason to review the choice of medicine when weight is a central goal, since newer options such as SGLT2 inhibitors and GLP-1 receptor agonists lower both blood sugar and weight. Practical steps help: eat at regular intervals and include protein and fibre so that a dip in blood sugar does not turn into a snack, ask your doctor whether a different dose, a different class or a combination would suit you better, and never stop or reduce a diabetes tablet on your own because of weight.
Medical
Clinical Definition
Sulphonylureas are insulin secretagogues that close adenosine triphosphate sensitive potassium channels in pancreatic beta cells, causing membrane depolarisation, calcium influx and insulin release. The resulting hyperinsulinaemia is the principal driver of their weight effect, acting through promotion of lipogenesis and reduced hepatic glucose output, sodium and fluid retention, and counter-regulatory eating after hypoglycaemia. Randomised and observational data give a consistent estimate of a 1.5 to 4 kg mean gain over six to twelve months, with wide individual variation and a plateau after the first year or two. In ADOPT, 4,360 patients with recently diagnosed type 2 diabetes were randomised to rosiglitazone, metformin or glyburide and followed for a median of about four years: glyburide produced a mean weight gain of about 1.6 kg during the first year which subsequently stabilised, rosiglitazone produced a gain approaching 5 kg over four years, and metformin produced weight loss of approximately 3 kg. UKPDS showed that over ten years weight gain was greatest with insulin at roughly 4 to 5 kg, intermediate with chlorpropamide and glibenclamide, and least with metformin or conventional dietary treatment, with metformin the only established oral agent that is essentially weight neutral. Comparative data also show less favourable glycaemic durability than metformin and a higher frequency of hypoglycaemia, which is greatest with glibenclamide in older patients and in renal impairment because its weakly active metabolites accumulate as the estimated glomerular filtration rate falls. Weight effects are compounded when a sulphonylurea is combined with insulin or a thiazolidinedione. For a patient whose weight is a central clinical concern, agents with weight neutral or weight lowering profiles, including metformin, sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists and the newer dual incretin agonists, should be considered in preference where clinically appropriate and affordable, but sulphonylureas remain a legitimate and often necessary choice where cost, availability, tolerance or the need for rapid glucose lowering dictate otherwise, and they remain the standard comparator for glycaemic durability. If weight rises following initiation or an increase in dose, the appropriate response is a structured medication review with attention to hypoglycaemia and glycaemic control, not unsupervised dose reduction by the patient.
Key Insight
Why It Matters
Sulphonylurea weight gain is small, dose-related and predictable, so the question is not whether the tablets lower glucose but whether their weight profile fits a patient whose main goal is weight.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: September 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
